Successful Treatment with Sulbactam-Durlobactam for Severe Acute Pancreatitis Complicated by Extensively Drug-Resistant Acinetobacter baumannii Infection at Multiple Sites: A Case Report.

BACKGROUND

The management of severe acute pancreatitis (SAP) complicated by multi-site infections with extensively drug-resistant Acinetobacter baumannii (XDR-AB) represents a critical therapeutic challenge. This report describes, to our knowledge, an early successful application of sulbactam-durlobactam in an SAP patient with concurrent XDR-AB infections in the abdomen, biliary tract and lungs.

CASE PRESENTATION: A 36-year-old female with hypertriglyceridemic SAP developed infections at multiple sites, with cultures consistently yielding XDR-AB. After the failure of multiple last-line antimicrobial regimens, therapy was switched to sulbactam-durlobactam combined with meropenem. This change was followed by a substantial clinical improvement: body temperature normalized, infection biomarkers decreased significantly and microbiological clearance of XDR-AB from all sites was achieved, leading to successful liberation from mechanical ventilation and discharge from the ICU.

CONCLUSION

This case demonstrates that sulbactam-durlobactam can be a highly effective therapeutic option for achieving both clinical and microbiological cure in complex SAP cases with multi-site XDR-AB infections that are refractory to conventional treatment regimens. It contributes early real-world evidence supporting a new therapeutic strategy for managing such life-threatening, complex infections.